Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1452W HIGH $21.75
Volume
13.04 K
Value Traded
103.38 K
Short % Float
0.67%
Days to Cover
1.0
+1.21%Week
-43.95%1 Month
-55.36%3 Month
-62.66%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.66 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
1.32 M
Float Shares
1.34 M
Insiders
0.37%
Institutions
1.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VRAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Virax Biolabs Group Limited
Past FDA Catalysts and PDUFA Decisions
How VRAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Virax Biolabs Group Limited is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every VRAX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ViraxImmune™ | Long COVID and related post-acute infection syndromes | 2026-05-26 | 88% specificity; 92% positive predictive valueRead More | Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection SyndromesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VRAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VRAX for Q2 2026. | ||||
VRAX Institutional Ownership Trends
VRAX Short Interest
Shares sold short, counted twice a month.
0.67%
Short % of Float
of tradable shares sold short
9.0K
Shares Sold Short
+35.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
343.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VRAX ranks across every disease it competes in
Competitive Position is a premium feature
See how VRAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVRAX News
-VRAX
Oct 29, 2026▲ +4.2%today
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
Virax Biolabs has signed three non-exclusive distribution agreements in China for its ImmuneSelect research products. The distributors will target specific customer segments across major biotech hubs, enhancing local sales and support. This strategy aims to leverage established networks to boost product evaluations and recurring sales.
Read more →-VRAX
Jul 16, 2026▲ +13%on this news
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Virax Biolabs' CEO James Foster provided a shareholder update following the fiscal 2026 Annual Report, highlighting the company's financial position and recent developments. The report indicates cash of $6.4 million and a successful $3.3 million financing. Additionally, a commercial supply agreement with Fosun Diagnostics was established to enhance market presence in Southeast Asia. Despite these advancements, the company's market valuation does not reflect its financial health.
Read more →-VRAX
Jul 10, 2026Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Virax Biolabs Group Limited has successfully closed the exercise of preferred investment options, generating approximately $3.3 million in gross proceeds. The options allowed for the purchase of 548,000 ordinary shares at a reduced exercise price of $6.00. The company intends to utilize the funds for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering.
Read more →-VRAX
Jul 9, 2026▼ -28.9%on this news· ran to -58% by day 3shared move
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Virax Biolabs Group Limited announced the exercise of preferred investment options, generating approximately $3.3 million in gross proceeds. The company will issue new Series A and B Preferred Investment Options at a reduced exercise price of $6.00 per share. The offering is anticipated to close around July 10, 2026, pending customary conditions.
Read more →-VRAX
Jul 9, 2026▲ +100%on this newsshared move
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Virax Biolabs has signed an exclusive supply agreement with Fosun Diagnostics to distribute its ImmuneSelect immune profiling products across six Southeast Asian countries. This partnership aims to enhance commercial opportunities and expand Virax's market presence. The agreement includes provisions for phased expansion and immediate product supply, focusing initially on tuberculosis-related research in Thailand.
Read more →-VRAX
Jun 24, 2026▼ -14.8%on this news
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
Virax Biolabs Group Limited has announced a 1-for-25 share consolidation effective June 26, 2026. This decision was approved by shareholders to help the company comply with Nasdaq's minimum bid price requirement. The consolidation will not affect shareholders' percentage interests, and the company's shares will continue trading under the symbol 'VRAX'.
Read more →-VRAX
May 26, 2026▼ -18.2%on this news· ran to -32% by day 3
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Virax Biolabs has reported positive early pilot data for its ViraxImmune™ test, designed for Long COVID and related syndromes. The test demonstrated 88% specificity and 92% positive predictive value in distinguishing patients from healthy controls. The company is preparing for a larger clinical validation involving 300 participants, with results expected in early 2027. This development could significantly enhance diagnostic strategies in an area with considerable unmet needs.
Read more →-VRAX
May 22, 2026▼ -9.3%on this news· ran to -31% by day 3shared move
filed as part of the Form 6-K report containing the Notice of Meeting and Proxy Statement in substitution for, and to the exclusion of, the existing amended and restated memorandum and articles of association of the Comp
Virax Biolabs Group Limited has scheduled an Extraordinary General Meeting for June 5, 2026, where shareholders will vote on several proposals, including a share consolidation. The Board of Directors encourages shareholders to participate, either in person or virtually. Shareholders of record by May 18, 2026, are entitled to vote, and methods for proxy voting have been provided. The meeting aims to foster shareholder engagement and streamline operations through the proposed consolidation of shares.
Read more →-VRAX
Apr 14, 2026▼ -11.1%on this news
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders Virax Biolabs is advancing a focused strategy centered on ViraxImmune and a U.S. market-entry pathway, whic
Virax Biolabs' CEO James Foster detailed the company's strategic priorities and upcoming milestones in a recent letter to shareholders. Focused on the development of ViraxImmune, the company aims to target post-acute infection syndromes, which are currently underdiagnosed. With a strong balance sheet and no debt, Virax is advancing towards U.S. market entry through a Laboratory Developed Test pathway. Upcoming milestones over the next few months include important data readouts that may validate their assay and inform future commercialization efforts.
Read more →-VRAX
Mar 31, 2026▲ +35.3%on this news
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Virax Biolabs has achieved ISO 13485:2016 and ISO 9001:2015 certifications, enhancing its quality management systems. These certifications support the company's strategy for regulated in vitro diagnostic development and U.S. clinical validation. Virax is also exploring U.S. laboratory-based testing services, including potential laboratory-developed tests.
Read more →-VRAX
Jan 30, 2026filed as part of the Form 6-K. Administration . The 2026 Plan will be administered by the Compensation Committee. The Committee may delegate any or all of the authority of the Committee with respect to Awards to Grantees
Virax Biolabs Group Limited is set to hold its Annual General Meeting (AGM) on March 11, 2026, at BioCity Glasgow. The meeting will address various proposals, including the adoption of the 2026 Equity Incentive Plan and the re-appointment of directors. Shareholders eligible to vote must hold shares as of January 12, 2026, and are encouraged to submit proxies if unable to attend. Clear voting procedures are outlined to facilitate shareholder participation.
Read more →-VRAX
Dec 4, 2025Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs Group Limited closed a $5 million private placement, enhancing its cash runway into the first half of 2028. The funds will support the completion of regulatory studies for long COVID in the US and UK. The company also plans to expand its immune-profiling platform and partnerships.
Read more →-VRAX
Dec 3, 2025▲ +75.1%on this newsshared move
Virax Biolabs Group Limited Announces $5 Million Private Placement
Virax Biolabs Group Limited has announced a successful private placement, securing $5 million by selling 12.5 million ordinary shares at a price of $0.40 each. The proceeds will be utilized for working capital and other corporate uses. The closing of the private placement is anticipated on December 4, 2025, pending customary conditions. H.C. Wainwright & Co. will act as the exclusive placement agent for this transaction, which involves preferred investment options with an exercise price of $0.40. Virax continues to focus on immunology and diagnostic innovations.
Read more →-VRAX
Dec 2, 2025Unaudited Condensed Consolidated Interim Financial Statements as of
VIRAX Biolabs Group Limited released its unaudited interim financial statements for the six months ending September 30, 2025. The results show a net loss of $2.34 million, with total assets of $5.71 million. While the company is developing its ViraxImmune assay to detect immune responses to various conditions, it faces challenges, including a high operating loss and decreased cash flow. Liabilities have significantly reduced, but the company still shows concerns with its current asset position.
Read more →-VRAX
Aug 26, 2025▼ -18.2%on this newsshared move
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Virax Biolabs has partnered with Emory University to conduct clinical studies on ViraxImmune™, targeting immune profiling in individuals with post-viral syndromes, particularly long COVID. This collaboration aims to advance diagnostics and improve patient outcomes. The company is also preparing for an FDA pre-submission meeting scheduled for early September.
Read more →-VRAX
Mar 18, 2025Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes LONDON
Virax Biolabs has initiated patient enrollment for a multi-center clinical study in the UK that aims to evaluate T cell dysfunction in post-acute infection syndromes, including long COVID and other conditions. The study, conducted in partnership with the NHS, will involve up to 200 participants, with results expected by Q2 2026. This research seeks to address the lack of reliable diagnostics for these syndromes and improve patient care through enhanced immune health assessments.
Read more →-VRAX
Mar 13, 2025▼ -12.3%on this newsshared move
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19 th World Immune Regulation Meeting LONDON, 
Virax Biolabs Group Limited presented significant data on T-Cell dysfunction associated with post-acute infection syndromes at the World Immune Regulation Meeting in Davos. The data suggests that chronic infections lead to progressive T-Cell exhaustion, which could impair immune response. The company plans to conduct clinical validation studies to explore the relationship between T-Cell dysfunction and various chronic conditions like long COVID and chronic fatigue. This research is aimed at enhancing diagnostic capabilities to better manage post-viral syndromes.
Read more →-VRAX
Mar 5, 2025▼ -7.5%on this news
Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs Group Limited will present its work on T cell dysfunction in post-acute infection syndromes at the upcoming 19th World Immune Regulation Meeting in Davos, Switzerland, taking place from March 12-15, 2025. Dr. Nigel McCracken, the Chief Operating Officer, will lead the presentation. The event is expected to host around 600 scientists and clinicians discussing advancements in immunology, and Virax will also showcase their immune profiling products at a designated booth.
Read more →-VRAX
Feb 25, 2025Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy Company Positioned to Support Public Health through Vaccine Efficacy Testing
Virax Biolabs Group Limited has expressed its belief that its technology is in alignment with the U.S. Department of Health and Human Services' push for transparency regarding vaccine efficacy. The company aims to support public health by providing tools for measuring vaccine effectiveness and monitoring immune profiles. Additionally, Virax is focused on advancing research related to protective immunity and T cell dysfunction, emphasizing its commitment to empowering individuals in their health decisions. CEO James Foster highlighted the company's readiness to contribute to vaccine efficacy testing as part of broader public health initiatives.
Read more →-VRAX
Dec 17, 2024▲ +10.4%on this news· ran to +54% by day 1
Virax Biolabs' CEO James Foster Issues Letter to Shareholders LONDON
Virax Biolabs' CEO James Foster has communicated the company's plans for 2025 in a letter to shareholders. Key achievements in 2024 include the launch of the ImmuneSelect portfolio and the initiation of a clinical study assessing the ViraxImmune IVD platform in post-acute infection syndrome patients. The company is focused on expanding distribution partnerships and preparing for U.S. regulatory submissions. Financially, Virax has reported a robust cash position with no long-term debt, aiming for significant advancements in immune diagnostic solutions in the coming year.
Read more →About Virax Biolabs Group Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next VRAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime